410 related articles for article (PubMed ID: 15865223)
21. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
22. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.
Boschi A; Tinelli C; Ortolani P; Moscatelli G; Morigi G; Arlotti M
AIDS; 2004 Dec; 18(18):2381-9. PubMed ID: 15622314
[TBL] [Abstract][Full Text] [Related]
23. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
24. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
25. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
26. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
28. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
[TBL] [Abstract][Full Text] [Related]
29. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.
Liu J; Wyatt LS; Amara RR; Moss B; Robinson HL
Vaccine; 2006 Apr; 24(16):3332-9. PubMed ID: 16472543
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.
Cosma A; Nagaraj R; Bühler S; Hinkula J; Busch DH; Sutter G; Goebel FD; Erfle V
Vaccine; 2003 Dec; 22(1):21-9. PubMed ID: 14604567
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
32. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
[TBL] [Abstract][Full Text] [Related]
33. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
34. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
35. Defective rev response element (RRE) and rev gene in HAART treated AIDS patients with discordance between viral load and CD4+ T-cell counts.
Saurya S; Lichtenstein Z; Karpas A
J Clin Virol; 2005 Aug; 33(4):324-7. PubMed ID: 16005679
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.
de Goede AL; van Deutekom HW; Vrancken B; Schutten M; Allard SD; van Baalen CA; Osterhaus AD; Thielemans K; Aerts JL; Keşmir C; Lemey P; Gruters RA
AIDS; 2013 Nov; 27(17):2679-89. PubMed ID: 24149085
[TBL] [Abstract][Full Text] [Related]
37. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.
Haas G; Plikat U; Debré P; Lucchiari M; Katlama C; Dudoit Y; Bonduelle O; Bauer M; Ihlenfeldt HG; Jung G; Maier B; Meyerhans A; Autran B
J Immunol; 1996 Nov; 157(9):4212-21. PubMed ID: 8892659
[TBL] [Abstract][Full Text] [Related]
39. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
[TBL] [Abstract][Full Text] [Related]
40. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy.
Soriano-Sarabia N; Abad MA; Vallejo A; Gutiérrez S; Leal M
Clin Microbiol Infect; 2006 Mar; 12(3):290-3. PubMed ID: 16451419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
